‘Liquid Biopsies’ Could Help Spot Genetic Faults in Lung Cancer
News Mar 07, 2015
Blood samples could offer an alternative to tumour biopsies in lung cancer patients, according to European researchers.
Experts believe the findings could aid future research by overcoming the difficulty of accessing some tumour samples.
The researchers analyzed blood samples from patients with advanced non-small-cell lung cancer and looked for ‘circulating free DNA’ - bits of DNA shed from tumour cells that can be isolated from the blood.
They found that the tumour DNA present in blood samples could be used to identify different types of tumour-causing genetic faults in a gene called EGFR.
The study, published in the journal JAMA Oncology, analyzed blood samples from 97 patients who took part in the EURTAC clinical trial. And in 78 per cent of the blood samples tested, two important genetic faults were successfully identified.
Dr Dana Tsui, cancer genetics scientist at Cancer Research UK’s Cambridge Institute, said: “This important study shows the potential of ‘liquid biopsies’ in opening up new research opportunities - when previously it’s been difficult to get tumour samples from patients. This research adds to the growing evidence that getting tumour DNA from blood samples could be a reliable way to identify important genetic faults in lung cancer patients.
“The study also looks at the effect of different genetic faults within the EGFR molecule on patient survival - something that’s been difficult to answer before the development of this technology,” explained Tsui.
They found that the presence of a particular fault in EGFR found in DNA isolated from blood - called L858R - was linked to poorer survival than the second fault analyzed in the study.
The researchers believe their findings raise the question of whether the tumour DNA present in blood samples could offer a less invasive way of searching for key genetic faults in the future.
Dipstick Technology Enables Rapid Diagnosis AnywhereNews
A new Australian study has reported a revolutionary dipstick technology that allows DNA and RNA to be extracted from living organisms in as little as 30 seconds.READ MORE
Advanced Prostate Cancer: EMA Approves Abiraterone Combined With Hormone Therapy as First-line TreatmentNews
The prostate cancer drug abiraterone has been approved by the European Medicines Agency in combination with standard hormone therapy for use as a first-line treatment for advanced prostate cancer.READ MORE
Cancer Cells Prevent Immune Cells from Producing Cancer Killing ChemicalsNews
Researchers have identified a substance released by pancreatic cancer cells that protects them from attack by immune cells called macrophagesREAD MORE
Comments | 0 ADD COMMENT
3rd Annual NGS Data Analysis and Informatics Conference
Feb 08 - Feb 09, 2018
3rd Annual Genome Editing & Engineering Conference
Feb 08 - Feb 09, 2018